Optimizing β-Lactams against Tuberculosis

Am J Respir Crit Care Med. 2020 May 1;201(9):1155-1157. doi: 10.1164/rccm.201911-2149LE.

Authors

Veronique R de Jager¹, Naadira Vanker², Lize van der Merwe¹, Elana van Brakel¹, Morris Muliaditan³, Andreas H Diacon^{1

4}

Affiliations

¹ TASK Applied ScienceCape Town, South Africa.
² TASK LaboratoryCape Town, South Africa.
³ GlaxoSmithKlineStevenage, United Kingdomand.
⁴ Stellenbosch UniversityCape Town, South Africa.

No abstract available

Publication types

Letter

MeSH terms

Administration, Intravenous
Administration, Oral
Adult
Aged
Aged, 80 and over
Amoxicillin / administration & dosage
Amoxicillin / standards
Amoxicillin / therapeutic use*
Anti-Bacterial Agents / standards
Anti-Bacterial Agents / therapeutic use*
Clavulanic Acid / administration & dosage
Clavulanic Acid / standards
Clavulanic Acid / therapeutic use*
Drug Combinations
Female
Humans
Male
Meropenem / administration & dosage
Meropenem / standards
Meropenem / therapeutic use*
Microbial Sensitivity Tests
Middle Aged
Mycobacterium tuberculosis / drug effects*
Practice Guidelines as Topic
Tuberculosis / drug therapy*
World Health Organization
beta-Lactamase Inhibitors / standards
beta-Lactamase Inhibitors / therapeutic use*

Substances

Anti-Bacterial Agents
Drug Combinations
beta-Lactamase Inhibitors
Clavulanic Acid
Amoxicillin
Meropenem